Sei Investments Co. Increases Stake in AbbVie Inc. $ABBV

Sei Investments Co. boosted its stake in shares of AbbVie Inc. (NYSE:ABBV) by 46.5% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 688,752 shares of the company’s stock after purchasing an additional 218,518 shares during the period. Sei Investments Co.’s holdings in AbbVie were worth $127,843,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Brighton Jones LLC raised its stake in AbbVie by 17.4% in the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after acquiring an additional 3,401 shares during the last quarter. Revolve Wealth Partners LLC grew its stake in AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after purchasing an additional 3,064 shares during the last quarter. Vestmark Advisory Solutions Inc. increased its holdings in shares of AbbVie by 84.3% in the first quarter. Vestmark Advisory Solutions Inc. now owns 38,888 shares of the company’s stock valued at $8,148,000 after purchasing an additional 17,788 shares during the period. OneAscent Investment Solutions LLC purchased a new position in shares of AbbVie in the first quarter worth about $330,000. Finally, Kovitz Investment Group Partners LLC lifted its holdings in shares of AbbVie by 42.7% during the first quarter. Kovitz Investment Group Partners LLC now owns 93,218 shares of the company’s stock worth $19,531,000 after purchasing an additional 27,890 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Stock Performance

Shares of NYSE ABBV opened at $223.83 on Friday. The company’s fifty day moving average price is $227.47 and its 200 day moving average price is $209.31. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The company has a market capitalization of $395.59 billion, a PE ratio of 169.57, a price-to-earnings-growth ratio of 1.22 and a beta of 0.36. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.60 and a current ratio of 0.72.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The company had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. During the same quarter in the previous year, the company earned $3.00 earnings per share. The firm’s revenue for the quarter was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, research analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a dividend of $1.73 per share. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a yield of 3.1%. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio (DPR) is currently 496.97%.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on ABBV shares. UBS Group increased their price target on shares of AbbVie from $195.00 to $220.00 and gave the stock a “neutral” rating in a report on Friday, November 7th. Raymond James Financial set a $256.00 price objective on shares of AbbVie in a report on Monday, November 3rd. Bank of America raised their target price on shares of AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, October 8th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $289.00 price target (up from $284.00) on shares of AbbVie in a research report on Wednesday, November 5th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $243.85.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.